Editas Stock Today

EDIT -  USA Stock  

USD 11.87  0.73  6.55%

Market Performance
0 of 100
Odds Of Distress
Less than 3
Editas Medicine is selling for under 11.87 as of the 17th of May 2022; that is 6.55 percent up since the beginning of the trading day. The stock's last reported lowest price was 11.0. Editas Medicine has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Editas Medicine are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of August 2021 and ending today, the 17th of May 2022. Click here to learn more.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 68.4 M outstanding shares of which 11.11 M shares are currently shorted by private and institutional investors with about 5.0 trading days to cover. More on Editas Medicine

Editas Medicine Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Editas Medicine's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Editas Medicine or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Editas Medicine generated a negative expected return over the last 90 days
Editas Medicine has high historical volatility and very poor performance
Editas Medicine is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 25.54 M. Net Loss for the year was (192.5 M) with loss before overhead, payroll, taxes, and interest of (116.96 M).
Editas Medicine currently holds about 499.84 M in cash with (163.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.3.
Editas Medicine has a poor financial position based on the latest SEC disclosures
Roughly 74.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.benzinga.com: Editas Medicine Earnings Conference Call Is Coming Up, Heres What You Need To Know - Benzinga - Benzinga
Editas Medicine Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Editas Medicine SEC Filings
Editas Medicine SEC Filings Security & Exchange Commission EDGAR Reports
President CEO, DirectorKatrine Bosley  (View All)
Average Analyst Recommendation
Analysts covering Editas Medicine report their recommendations after researching Editas Medicine's financial statements, talking to executives and customers, or listening in on Editas Medicine's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Editas Medicine. The Editas consensus assessment is calculated by taking the average forecast from all of the analysts covering Editas Medicine.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Editas Medicine based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Editas Medicine financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares57.3 M67.6 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted57.3 M67.6 M
Fairly Down
Increasing
Slightly volatile
Total Assets569.6 M677.5 M
Fairly Down
Increasing
Slightly volatile
Total Liabilities139.9 M123.8 M
Moderately Up
Increasing
Slightly volatile
Current Assets443.6 M507.3 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities45.2 M46.9 M
Sufficiently Down
Increasing
Slightly volatile
Total Debt30.5 M26.4 M
Fairly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.0520.035
Way Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Editas Medicine's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Editas Medicine's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Editas Medicine's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Editas Medicine's financial leverage. It provides some insight into what part of Editas Medicine's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Editas Medicine's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Editas Medicine deploys its capital and how much of that capital is borrowed.
Liquidity
Editas Medicine cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 26.38 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Editas Medicine has a current ratio of 10.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Editas Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Editas Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Editas Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Editas to invest in growth at high rates of return. When we think about Editas Medicine's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(168.11 Million)Share
Editas Medicine (EDIT) is traded on NASDAQ Exchange in USA. It is located in 11 Hurley Street and employs 264 people. Editas Medicine is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 761.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Editas Medicine's market, we take the total number of its shares issued and multiply it by Editas Medicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Editas Medicine conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 68.4 M outstanding shares of which 11.11 M shares are currently shorted by private and institutional investors with about 5.0 trading days to cover. Editas Medicine currently holds about 499.84 M in cash with (163.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.3.
Check Editas Medicine Probability Of Bankruptcy
Ownership
Editas Medicine holds a total of sixty-eight million four hundred thousand outstanding shares. The majority of Editas Medicine outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Editas Medicine to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Editas Medicine. Please pay attention to any change in the institutional holdings of Editas Medicine as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Editas Ownership Details

Editas Stock Price Odds Analysis

What are Editas Medicine's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Editas Medicine jumping above the current price in 90 days from now is over 95.64%. The Editas Medicine probability density function shows the probability of Editas Medicine stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.8463 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Editas Medicine will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Editas Medicine is significantly underperforming DOW.
  Odds Below 11.87HorizonTargetOdds Above 11.87
4.33%90 days
 11.87 
95.64%
Based on a normal probability distribution, the odds of Editas Medicine to move above the current price in 90 days from now is over 95.64 (This Editas Medicine probability density function shows the probability of Editas Stock to fall within a particular range of prices over 90 days) .

Editas Medicine Historical Income Statement

Editas Medicine Income Statement is one of the three primary financial statements used for reporting Editas's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Editas Medicine revenue and expense. Editas Medicine Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Editas Medicine Gross Profit is comparatively stable at the moment as compared to the past year. Editas Medicine reported Gross Profit of 25.54 Million in 2021. Preferred Dividends Income Statement Impact is likely to gain to about 43.4 K in 2022, whereas Interest Expense is likely to drop (2.5 M) in 2022. View More Fundamentals

Editas Stock Against Markets

Picking the right benchmark for Editas Medicine stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Editas Medicine stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Editas Medicine is critical whether you are bullish or bearish towards Editas Medicine at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Editas Medicine without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Editas Medicine Corporate Directors

Editas Medicine corporate directors refer to members of an Editas Medicine board of directors. The board of directors generally takes responsibility for the Editas Medicine's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Editas Medicine's board members must vote for the resolution. The Editas Medicine board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Kevin Bitterman - Independent DirectorProfile
John Mendlein - Independent DirectorProfile
Boris Nikolic - Independent DirectorProfile
Doug Cole - Independent DirectorProfile

Investing Editas Medicine

You need to understand the risk of investing before taking a position in Editas Medicine. The danger of trading Editas Medicine is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Editas Medicine is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Editas Medicine. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Editas Medicine is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Investing Opportunities. Note that the Editas Medicine information on this page should be used as a complementary analysis to other Editas Medicine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Editas Stock analysis

When running Editas Medicine price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine Editas Medicine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.